 | | parties | date | size | eqty | roy. |
| | Acceptys,OncoMab / Patrys | 01/2007 | | | |
| | Human antibody technology and lead product candidates for cancer |
| | OncoMab / Bioceros | 09/2010 | | | |
| | Cripto-1 cancer monoclonal antibody |
| | DeveloGen / Evotec AG | 07/2010 | $33.3 | | |
| | Acq. for shares plus performance-related deferred payments |
| | Celsion Corp. / Duke University | 11/1999 | | | |
| | Heat-activated targeted drug delivery |
| | Orexigen Therapeutics / Takeda | 09/2010 | $1050.0 | | |
| | Contrave (naltrexone SR/bupropion SR) for obesity in NA |
| | BioArctic Neuroscience / Eisai | 12/2007 | | | |
| | BAN2401 humanized monoclonal antibody for Alzheimer’s disease |
| | Acceptys / Patrys | 10/2008 | | | |
| | Acq. for equity |
| | Biomoda / Saccomanno Research Institute | 09/2010 | | | |
| | CyPath labeling solution for the early detection of lung cancer |
| | Generex Biotechnology / Merck KGaA | 09/2010 | | | |
| | Distribution of Glucose RapidSpray in Mexico |
| | Almac Group / Merck KGaA,Medical Research Council | 04/2010 | | | |
| | Evaluation of biomarkers of response to cetuximab therapy in colorectal cancer samples |